

ARE WE IMPROVING THE ODDS OF SURVIVING CANCER? **OPTIMIZING ADJUVANT THERAPY IN HER2+ BREAST CANCER**



THURSDAY, 11 MAY 2023 | 18:30 – 19:30 CEST

Frankfurt Hall, Hub27, Berlin

OVERVIEW

The treatment of HER2+ early breast cancer has evolved significantly, improving patient's clinical outcomes. Join our expert faculty to discuss evolving clinical risk-based decision-making approaches for HER2-targeted therapy. Personalized patient communication will be at the heart of the discussion.

FACULTY



Prof. Christian Jackisch
Offenbach, Germany



Prof. Diana Lüftner
Brandenburg, Germany



Prof. Miguel Martin
Madrid, Spain

AGENDA

<p>18:30 – 18:35 Welcome and Introduction D. Lüftner</p>	<p>18:55 – 19:10 From Data to Practice: A Clinical Case Challenge C. Jackisch</p>
<p>18:35 – 18:45 Are We Taking the Right Choices? New Insights on Risk Assessment in Patients With HER2+ EBC C. Jackisch</p>	<p>19:10 – 19:25 Delivering the Continuum of Care: Setting Each Patient up for Treatment Success D. Lüftner</p>
<p>18:45 – 18:55 The Wise Move: Current Strategies in High-Risk HER2+ EBC M. Martin</p>	<p>19:25 – 19:30 Q&A and Closing Remarks D. Lüftner</p>